欧盟 - 丹麦文 - EMA (European Medicines Agency)

n.v. organon - ganirelix - reproductive techniques, assisted; ovulation induction; infertility, female - hypofysiske og hypotalamiske hormoner og analoger - forebyggelse af for tidlig luteiniserende hormonforstyrrelser hos kvinder, der gennemgår kontrolleret ovariehyperstimulering for assisterede reproduktionsteknikker. i kliniske undersøgelser, orgalutran blev brugt med rekombinant human follikel-stimulerende hormon eller corifollitropin alfa, vedvarende follikel stimulerende.

丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

stada arzneimittel ag - anastrozol - filmovertrukne tabletter - 1 mg

丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

accord healthcare b.v. - anastrozol - filmovertrukne tabletter - 1 mg

丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

bluefish pharmaceuticals ab - anastrozol - filmovertrukne tabletter - 1 mg

丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

medical valley invest ab - anastrozol - filmovertrukne tabletter - 1 mg

丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - anastrozol - filmovertrukne tabletter - 1 mg

丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

laboratoires juvisé pharmaceuticals - anastrozol - filmovertrukne tabletter - 1 mg

丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

bluefish pharmaceuticals ab - bicalutamid - filmovertrukne tabletter - 50 mg

丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

teva b.v. - bicalutamid - filmovertrukne tabletter - 50 mg

欧盟 - 丹麦文 - EMA (European Medicines Agency)

accord healthcare s.l.u. - degarelix acetate - prostatiske neoplasmer - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.